Biomarker Testing in Non-Small Cell Lung Cancer
New targeted therapy and immunotherapy regimens are frequently approved and added to the NCCN Guidelines® Non-Small Cell Lung Cancer. Newer testing methods are being developed for patients who are not medically fit for invasive testing. Oncologists should be familiar with the current biomarker testing recommendations to improve outcomes for their patients with metastatic NSCLC.
Category
  • Lung Cancers
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Smoking Cessation in Patients with Cancer
Providing care for patients with cancer who smoke poses unique challenges for oncology teams already managing a complex disease, and standardized guidance on effective smoking cessation interventions for patients with cancer is needed. NCCN recommends evidence-based approaches to pharmacotherapy and behavior therapy in order to help primary oncology teams to provide cessation support tailored to their patients’ needs.
Category
  • Lung Cancers
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Radiation Techniques in the Treatment of Lung Cancer
Multidisciplinary evaluations of patients with non-small cell lung cancer (NSCLC) should include radiation oncologists, because radiation therapy (RT) has a potential role in all stages of NSCLC.
Category
  • Lung Cancers
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Immunotherapies in Non-Small Cell Lung Cancer
Immunotherapy recommendations for patients with thoracic cancers are rapidly changing, and health care providers are challenged to remain aware of the most current recommendations in the NCCN Guidelines® to improve outcomes for their patients.
Category
  • Lung Cancers
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Recorded Presentation from the NCCN Oncology Case Manager and Medical Director Program: New Treatments for Metastatic Lung Cancer
The new combination immunotherapy + chemotherapy regimens represent a major change in systemic therapy for patients with metastatic NSCLC. Case managers and other health care providers have less experience with these new immunotherapy + chemotherapy regimens or the newer targeted therapies that have different mechanisms of action and side effects than traditional cytotoxic chemotherapy regimens.
Category
  • Lung Cancers
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Lung Cancer
For each of the emerging therapies described (bevacizumab, PARP inhibitors, and HIPEC), the treatment settings, patient selection criteria, and other therapies used in conjunction have varied widely across clinical trials. This has led to much discussion and likely confusion regarding the exact clinical contexts in which these new options should be considered.
Category
  • Lung Cancers
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Use of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Real-World Issues
Cancer immunotherapy is a rapidly growing and dynamic field, particularly for diseases such as lung cancer where immune checkpoint inhibitors are an important component of treatment.
Category
  • Lung Cancers
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Recorded Presentation from the NCCN Pharmacy Updates: Updates on the Use of Immunotherapy and Targeted Therapy in Non-Small Cell Lung Cancer
Many new options exist for the treatment of advanced non-small cell lung cancer (NSCLC) in addition to traditional platinum-based chemotherapy. Pharmacists should be aware of the new data and recommendations for immunotherapies and targeted therapies, and how they relate to improvements in clinical efficacy and quality of life. It is also important to be aware of the potential for unique and potentially severe adverse events that can occur with these therapies; therefore, pharmacists should educate patients about the possibility of adverse events and the need to report symptoms to their health care teams to avoid severe complications.
Category
  • Lung Cancers
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
New Targeted Therapies for Non-Small Cell Lung Cancer
The NCCN Guidelines® Non-Small Cell Lung Cancer are updated frequently throughout the year to include new approved agents and indications. It is difficult for clinicians to stay up-to-date on the most recent recommendations to improve outcomes for their patients with metastatic NSCLC. In addition, clinicians need to be aware of novel adverse reactions that may occur with the new targeted therapies.
Category
  • Lung Cancers
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Sequencing Therapy for Patients with Lung Cancer
The NCCN Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer Panels have recently started identifying and recommending preferred systemic therapy regimens for patients with NSCLC and small cell lung cancer based on clinical data and experience; because these are recent recommendations,
Category
  • Lung Cancers
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation